Virtu Announces First Quarter 2024 Results
April 24, 2024 06:00 ET
|
Virtu Financial, LLC
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative,...
Grab to Announce First Quarter 2024 Results on May 15, 2024
April 24, 2024 06:00 ET
|
Grab Holdings Limited
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Grab Holdings Limited (NASDAQ: GRAB, the “Company” or “Grab”), plans to announce its unaudited first quarter 2024 results after the U.S. market closes on...
HighPeak Energy, Inc. Announces 2024 First Quarter Earnings Release and Conference Call Dates
April 24, 2024 06:00 ET
|
HighPeak Energy, Inc.
HighPeak Energy, Inc. Announces 2024 First Quarter Earnings Release and Conference Call Dates
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
April 24, 2024 04:05 ET
|
Affimed N.V.
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been...
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Tower Semiconductor Announces First Quarter 2024 Financial Results and Conference Call
April 24, 2024 03:00 ET
|
Tower Semiconductor
MIGDAL HAEMEK, Israel – April 24, 2024 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, will issue its first quarter 2024 earnings release...
Futu Announces the Number of Its Clients in Malaysia Has Surpassed 100,000
April 24, 2024 02:30 ET
|
Futu Holdings Limited
HONG KONG, April 24, 2024 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced...
Pharming Group to report first quarter 2024 financial results on May 8
April 24, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial...